At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you. I would now ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year. If approved ...

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

EPS: US$1.65 (down from US$2.71 in 1Q 2024). Our free stock report includes 2 warning signs investors should be aware of before investing in Biogen. Read for free now. Revenue exceeded analyst ...

TOKYO -- Japanese drugmaker Eisai is overhauling its U.S. operations as the company seeks ways to overcome the hurdles to wide adoption of its flagship Alzheimer's disease treatment. The company ...

Executive Director & Video Game Industry Analyst at Circana (NPD) Mat Piscatella announced The Elder Scrolls IV: Oblivion Remastered after just one week is already the third best-selling game of ...

Texas A&M Aggies guard Wade Taylor IV is officially moving on to the next chapter of his basketball career. Taylor IV announced Saturday on Instagram that he's declaring for the 2025 NBA Draft ...

Trump recently joked he would like to be the pope as the Vatican prepares to vote for the next pontiff following Pope Francis’ death last month. Warren Buffett has remained quiet on Trump’s ...

“Thank you God for blessing me with the talents to play the game I love,” Hill wrote on X with a picture of his father and younger brother, Kameron, “and I want to thank everyone who helped ...

Just months after approval, it became clear that the drug, sold as Tysabri, also put some patients at risk of developing an often-fatal brain infection. Natalizumab returned in 2006 with a risk ...